Results 231 to 240 of about 113,669 (290)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Neuroleptic Malignant Syndrome on Chronic Trifluoperazine Therapy: A Diagnostic Dilemma. [PDF]

Clin Case Rep
Baral S, Bhattarai S, Joshi KC.
europepmc   +1 more source

The use of different types of networks, alone and in combination, for drug target identification

British Journal of Pharmacology, EarlyView.
Current therapeutic approaches often focus on targeting clinical symptoms or peripheral phenotypes rather than the underlying molecular mechanisms, or endophenotypes, that drive diseases. While symptom‐based drugs can alleviate discomfort, they do not necessarily alter disease progression and may overlook opportunities for prevention or early ...
Paolo Parini
wiley   +1 more source

Age- and Sex-Related Trends in Psychotropic Prescribing Among Youths in Denmark and the United States: 2010-2020. [PDF]

Pharmacoepidemiol Drug Saf
Tran P, Rasmussen L, Amill-Rosario A, Bliddal M, dosReis S, Wesselhoeft R.   +5 more
europepmc   +1 more source

Simultaneous Determination of Fourteen Antipsychotic Drugs in Whole Blood by Solid Phase Extraction and Liquid Chromatography Tandem Mass Spectrometry

, 2019
Theresa M Dawe
openalex   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Dual long-acting injectable antipsychotic use in treatment-resistant schizophrenia with extensive hospitalization history: A case report. [PDF]

Ment Health Clin
Zheng L, Jhawar A.
europepmc   +1 more source

Mechanism of Action of Antipsychotics, Haloperidol and Olanzapine in vitro

, 2001
Vijaylaxmi Mahapatra
openalex   +1 more source

Diabetes mellitus and associated factors among psychiatric patients receiving antipsychotic treatment at Wachemo University Nigist Elleni Hospital, South Ethiopia. [PDF]

PLoS One
Laemango AM, Begna MB, Masebo DT, Anshebo DL, Woyesa SB, Funga ML.   +5 more
europepmc   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source